We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.68B
1-Year Est. Return 375.52%
This Fund
S&P 500
This Quarter Est. Return
-7.2%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$448M
AUM Growth
+$15.9M
Cap. Flow
+$65.5M
Cap. Flow %
14.64%
Top 10 Hldgs %
71.5%
Holding
29
New
4
Increased
9
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$29.6M
2
BLU
BELLUS Health Inc.
BLU
+$16.2M
3
KURA icon
Kura Oncology
KURA
+$11.2M
4
IMUX icon
Immunic
IMUX
+$10.3M
5
MRUS
Merus
MRUS
+$8.51M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$14.8M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$13.3M
3
ALLK
Allakos
ALLK
+$7.99M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.88M
5
KRON
Kronos Bio
KRON
+$4.06M

Sector Composition

Rank Sector Weight
1 Healthcare 99.45%
2 Financials 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
26
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.47M 0.55%
250,000
– –
MREO
27
Mereo BioPharma
MREO
$38.7M
$2.19M 0.49%
1,954,970
– –
ALLK
28
DELISTED
Allakos
ALLK
– –
-815,667
Closed -$7.99M
KRON
29
DELISTED
Kronos Bio
KRON
– –
-298,839
Closed -$4.06M
1
2

Similar funds

TNBTD
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
HCA
Heck Capital Advisors Rhinelander, Wisconsin $1.67B AUM 26.33% 1-Year Est. Return

Commodore Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Commodore Capital held 29 positions worth $448M, up 3.7% from $432M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Commodore Capital deployed $65.5M of net new capital in Q1 2022, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Karyopharm Therapeutics: 237,403 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $14.8M trimmed.

  • Commodore Capital's largest Q1 2022 buy was Karyopharm Therapeutics: 237,403 shares worth $26.2M.
  • Commodore Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $16.2M increase.
  • Commodore Capital's biggest Q1 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $14.8M.
  • Commodore Capital fully exited Allakos in Q1 2022, selling an estimated $7.99M.
  • Commodore Capital's ten largest holdings make up 72% of its $448M portfolio in Q1 2022.
  • Commodore Capital opened 4 new positions and closed 2 in Q1 2022.
  • Commodore Capital's portfolio value rose 3.7% quarter-over-quarter to $448M.

Based on Commodore Capital's 13F filing for Q1 2022, filed 16 May 2022.